✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Novartis AG is placed ninth on our list among the best cancer stocks.

TheFly reported on January 6 that Barclays upgraded NVS to Equal Weight from Underweight with a CHF 120 price target after a coverage transfer. Barclays noted a poor operational outlook for 2026 and stated that the company’s “fairly rich” pipeline is mostly reflected in valuation and faces competition.

In other news, Novartis AG (NYSE:NVS) unveiled a 35,000-square-foot RLT facility in Winter Park, Florida, on January 9. This is the company’s fourth U.S. location and a component of its $23 billion U.S. investment strategy. The facility handles specific, time-sensitive logistics and was built to support precision oncology treatments such as Pluvicto and Lutathera.

Novartis AG is a global biopharmaceutical leader with a robust oncology portfolio, including over 30 high-value therapies and a growing radioligand therapy (RLT) pipeline. The company invests heavily in precision oncology, advanced manufacturing, and targeted treatments like Pluvicto and Lutathera to address complex cancer needs worldwide.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.